Αρχική World News FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR... World News FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer Από Ogkologos - 9 Μαΐου, 2025 620 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma 10 Αυγούστου, 2023 EMA Recommends Granting a Marketing Authorisation for Quizartinib 2 Οκτωβρίου, 2023 First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable... 5 Ιουλίου, 2021 Exercising While Living With Peripheral Neuropathy: What People Diagnosed With Cancer... 2 Μαΐου, 2023 Φόρτωση περισσοτέρων HOT NEWS A Large Case-Control Study of Hodgkin Lymphoma Survivors Suggests a Dose-Response... Sen. Amy Klobuchar Announces Breast Cancer Diagnosis, Urges Women Not to... Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence... The Timing for the Age of which Natural Menopause Occurs